Estimating the prevalence of non-cervical human papillomavirus infection in mainland China (PROGRESS-Plus): protocol of a national cross-sectional study.

Autor:	Wang W; Merck & Co Inc, Rahway, New Jersey, USA wei.wang40@merck.com., Kothari-Talwar S; Merck & Co Inc, Rahway, New Jersey, USA., Roberts C; Merck & Co Inc, Rahway, New Jersey, USA., Lu Q; School of Public Health, Peking University, Beijing, China., Lara N; IMS Health Barcelona, Barcelona, Spain., Panchal R; IQVIA, Bangalore, India., Morais E; MSD France, Courbevoie, France., Chen YT; Merck & Co Inc, Rahway, New Jersey, USA., Qiao Y; Cancer Epidemiology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Cui F; Peking University Health Science Centre, Beijing, China.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2023 Feb 02; Vol. 13 (2), pp. e065749. Date of Electronic Publication: 2023 Feb 02.
DOI:	10.1136/bmjopen-2022-065749
Abstrakt:	Introduction: Human papillomavirus (HPV) infection is the most common sexually transmissible infection worldwide. Although the prevalence of cervical HPV infection has been extensively reported in women worldwide, few epidemiological studies have examined the prevalence of non-cervical HPV infection among both women and men, especially in China. Methods and Analysis: PROGRESS-Plus is a national, multisite, cross-sectional study that aims to estimate the prevalence of non-cervical HPV infection in women and men aged 18-60 years residing in mainland China. More specifically, PROGRESS-Plus will estimate the prevalence rate of HPV DNA in oral samples from both women and men, and that of anogenital samples from men. The secondary study objectives are to (1) report the aforementioned prevalence rates by HPV genotype, age and geographical region, (2) examine the concordance (ie, prevalence of the same HPV genotype) between the oral and anogenital samples among men, (3) explore risk factors associated with oral (in both women and men) and anogenital (in men only) HPV infection and (4) describe study participants' health-related quality of life, health behaviour, sexual behaviour and health status. Ethics and Dissemination: The study protocol and all required documents have been submitted for review and approval to the Independent Ethics Committees of all the participating sites. All participants will provide their written informed consent on study entry, and all the recorded data will be treated as confidential. Competing Interests: Competing interests: The PROGRESS-Plus study is sponsored by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu